The European healthcare technology and medical device ecosystem has entered an era of disciplined maturity. The speculative valuation inflation of the early 2020s has given way to a metrics-driven environment where strategic value is defined by clinical utility, regulatory resilience and technological defensibility. Within this landscape, European founders face a structural reality: domestic exit options are frequently constrained by fragmented national healthcare systems, lo